A facile approach to preparing personalized cancer vaccines using iron-based metal organic framework

Front Immunol. 2024 Jan 8:14:1328379. doi: 10.3389/fimmu.2023.1328379. eCollection 2023.

Abstract

Background: Considering the diversity of tumors, it is of great significance to develop a simple, effective, and low-cost method to prepare personalized cancer vaccines.

Methods: In this study, a facile one-pot synthetic route was developed to prepare cancer vaccines using model antigen or autologous tumor antigens based on the coordination interaction between Fe3+ ions and endogenous fumarate ligands.

Results: Herein, Fe-based metal organic framework can effectively encapsulate tumor antigens with high loading efficiency more than 80%, and act as both delivery system and adjuvants for tumor antigens. By adjusting the synthesis parameters, the obtained cancer vaccines are easily tailored from microscale rod-like morphology with lengths of about 0.8 μm (OVA-ML) to nanoscale morphology with sizes of about 50~80 nm (OVA-MS). When cocultured with antigen-presenting cells, nanoscale cancer vaccines more effectively enhance antigen uptake and Th1 cytokine secretion than microscale ones. Nanoscale cancer vaccines (OVA-MS, dLLC-MS) more effectively enhance lymph node targeting and cross-presentation of tumor antigens, mount antitumor immunity, and inhibit the growth of established tumor in tumor-bearing mice, compared with microscale cancer vaccines (OVA-ML, dLLC-ML) and free tumor antigens.

Conclusions: Our work paves the ways for a facile, rapid, and low-cost preparation approach for personalized cancer vaccines.

Keywords: adjuvants; cancer immunotherapy; endogenous fumarate ligands; ferric ions; metal organic framework; nanotechnology; personalized cancer vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Neoplasm
  • Autoantigens
  • Cancer Vaccines*
  • Iron
  • Metal-Organic Frameworks*
  • Mice
  • Neoplasms* / therapy

Substances

  • Cancer Vaccines
  • Metal-Organic Frameworks
  • Autoantigens
  • Iron
  • Antigens, Neoplasm

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. We gratefully acknowledge the financial support from Japan Society for the Promotion of Science (JSPS, KAKENHI Grant No. 23K04555 and 22K20517), Takeda Science Foundation, and NIMS funds. This work was supported in part by “Advanced Research Infrastructure for Materials and Nanotechnology in Japan (ARIM)” of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. Proposal Number JPMXP1223NM5201.